Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | NAMPT | P43490 | 6/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.31 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4125819 | 0.94 | PTGS2 (0.33) | PTGS2NAMPTATMSMN1; SMN2KDM4E | |
| SCHEMBL3700227 | 0.93 | NAMPT (0.32) | PTGS2NAMPTLIMK2 | |
| SCHEMBL4130428 | 0.93 | SLC16A3 (0.34) | PTGS2NAMPTATMSMN1; SMN2SLC16A3 | |
| SCHEMBL3699795 | 0.91 | P2RX7 (0.34) | PTGS2NAMPTKDM4EALDH1A1LMNA | |
| SCHEMBL4119622 | 0.91 | RIPK1 (0.36) | NAMPTKDM4EALDH1A1LMNAGAA | |
| SCHEMBL3693029 | 0.90 | ALDH1A1 (0.39) | ATMSMN1; SMN2SLC16A3SLC16A1KDM4E | |
| SCHEMBL4130995 | 0.88 | NAMPT (0.36) | NAMPT | |
| SCHEMBL4200027 | 0.88 | MEN1 (0.32) | ALDH1A1 | |
| SCHEMBL4200021 | 0.88 | HTR2C (0.36) | SLC16A3SLC16A1ALDH1A1 | |
| SCHEMBL4127061 | 0.88 | SLC16A3 (0.34) | SMN1; SMN2SLC16A3SLC16A1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | PTGS2 269/4885NAMPT 2129/4885ATM 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.